Is Medtronic Plc overvalued or undervalued?

As of 16 June 2025, the valuation grade for Medtronic Plc has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued based on its financial metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 15.42, and a PEG ratio of 1.00, which suggests that the stock is reasonably priced relative to its growth expectations.
In comparison to peers, Medtronic's P/E ratio of 20.86 is lower than Abbott Laboratories at 19.12 and significantly lower than Intuitive Surgical, Inc., which has a P/E of 73.45, indicating that Medtronic may offer better value. Additionally, its EV to EBITDA ratio is more favorable than that of Thermo Fisher Scientific, which stands at 17.94. Despite a recent decline in stock price compared to the S&P 500, Medtronic's strong fundamentals and attractive valuation ratios suggest it is a compelling investment opportunity.